FREE TREATMENT REPORT

See ratings and reviews when you sign up for an account.

Atomoxetine in Adolescents With Attention Deficit Hyperactivity Disorder (ADHD) and Substance Use Disorder (SUD)

This study is currently Recruiting

September 2009 By National Institute on Drug Abuse (NIDA)

First Recieved on September 16, 2005

Last Updated on September 2, 2009

Sponsor: National Institute on Drug Abuse (NIDA)
Collaborators:
Information provided by: National Institute on Drug Abuse (NIDA)
Identifier: NCT00218322

Purpose

Adolescents with attention deficit hyperactivity disorder (ADHD) often develop substance use disorders (SUD). The purpose of this study is to evaluate the effectiveness of atomoxetine in treating adolescents dually diagnosed with ADHD and SUD.

Study Type: Interventional
Study Design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Eligibility

Ages Eligible for Study:15 Years
Genders Eligible for Study:Both
Accepts Healthy Volunteers:No
Criteria

Inclusion Criteria: - DSM-IV diagnosis of ADHD - Current or recent (within the three months prior to study entry) SUD, including marijuana and alcohol abuse - ADHD CGI-S score of greater to or equal to 4 Exclusion Criteria: - Any Unstable medical condition - Recent history of intravenous drug use or cocaine dependence - Currently abusing ecstasy, cocaine, gamma-hydroxybutyrate, methamphetamine, amphetamine, opioids, phencyclidine, or benzodiazepine - Mental retardation or organic brain syndrome - Currently psychotic or history of bipolar disorder - Currently taking any psychotropic or anti-substance abuse disorder medications - Current DSM-IV diagnosis of major depression, depressive disorder, or anorexia - Pregnant or breastfeeding

Investigators

  • Investigator: Timothy E. Wilens - Principal Investigator - Massachusetts General Hospital

Locations

  • Massachusetts General Hospital

    Boston, Massachusetts 02114 United States

advertisement
V2012.311.925.327
Disclaimer: The list and ratings above are for informational purposes only, and is intended to supplement, not substitute for, the expertise and judgment of your physician, pharmacist or other healthcare professional. The goal of the information is to provide you with a comprehensive view of all available treatments, but should not be construed to indicate that use of any one treatment is safe, appropriate, or effective for you. Decisions about use of a new treatment, or about a change in your current treatment plan, should be in consultation with your doctor or other healthcare professional.